Literature DB >> 9046341

Meta-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors.

G M Ksander1, R de Jesus, A Yuan, R D Ghai, C McMartin, R Bohacek.   

Abstract

The design, synthesis, and biochemical profile of meta-substituted benzofused macrocyclic lactams are described. The meta-substituted benzofused macrocyclic lactams were designed to have a degree of flexibility allowing the amide bond to occupy two completely different conformations while maintaining sufficient rigidity to allow for strong interaction between enzyme and inhibitor. Using TFIT, a novel molecular superimposition program, it was shown that the meta analogs could be readily superimposed onto our ACE inhibitor template whereas no low-energy superimpositions of the ortho-substituted macrocycles could be found. The macrocycles were prepared by tethering aldehyde 1 derived from S-glutamic acid or S-aspartic acid to a meta-substituted phosphonium bromide 2. Homologation to a monocarboxylic acid methyl ester malonate followed by deprotection and cyclization gave the macrocyclic frame. Further manipulation gave the desired compounds. Unlike the ortho-substituted benzofused macrocyclic lactams described in the previous paper which are selective NEP inhibitors, the meta-substituted compounds are dual inhibitors of both NEP and ACE. The most potent member of this new series, compound 16a, inhibited both enzymes with an IC50 = 8 nM in NEP and 4 nM in ACE.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9046341     DOI: 10.1021/jm960583g

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Crystal structure of Mycobacterium tuberculosis zinc-dependent metalloprotease-1 (Zmp1), a metalloprotease involved in pathogenicity.

Authors:  Davide M Ferraris; Diego Sbardella; Agnese Petrera; Stefano Marini; Beat Amstutz; Massimo Coletta; Peter Sander; Menico Rizzi
Journal:  J Biol Chem       Date:  2011-08-03       Impact factor: 5.157

2.  QXP: powerful, rapid computer algorithms for structure-based drug design.

Authors:  C McMartin; R S Bohacek
Journal:  J Comput Aided Mol Des       Date:  1997-07       Impact factor: 3.686

3.  Identification of novel small-molecule inducers of fetal hemoglobin using pharmacophore and 'PSEUDO' receptor models.

Authors:  Regine Bohacek; Michael S Boosalis; Colin McMartin; Douglas V Faller; Susan P Perrine
Journal:  Chem Biol Drug Des       Date:  2006-05       Impact factor: 2.817

4.  Synthesis and in silico screening of a library of β-carboline-containing compounds.

Authors:  Kay M Brummond; John R Goodell; Matthew G Laporte; Lirong Wang; Xiang-Qun Xie
Journal:  Beilstein J Org Chem       Date:  2012-07-10       Impact factor: 2.883

5.  Modular, One-Pot, Sequential Aziridine Ring Opening-S(N)Ar Strategy to 7-, 10-, and 11-Membered Benzo-Fused Sultams.

Authors:  Joanna K Loh; Naeem Asad; Thiwanka B Samarakoon; Paul R Hanson
Journal:  J Org Chem       Date:  2015-10-08       Impact factor: 4.354

6.  Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin-Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme.

Authors:  Urvashi Sharma; Gyles E Cozier; Edward D Sturrock; K Ravi Acharya
Journal:  J Med Chem       Date:  2020-05-08       Impact factor: 7.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.